nach oben

Erschienen in:

25.06.2020 | Letter to the Editors

Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy

verfasst von: Melissa J. Danesh, Patrick M. Mulvaney, Naoka Murakami, Leonardo V. Riella, Ann W. Silk, Glenn J. Hanna, Chrysalyne D. Schmults

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor, …

Abdel-Wahab N, Safa H, Abudayyeh A et al (2019) Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J ImmunoTher Cancer 7(1):106CrossRef

Gupta S, Cortazar FB, Riella LV, Leaf DE (2020) Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney 1(2):130–140CrossRef

Barnett R, Barta VS, Jhaveri KD (2017) Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab. N Engl J Med 376(2):191–192CrossRef

Tian T, Li X, Zhang J (2019) mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci 20:3

US National Library of Medicine. Tacrolimus, nivolumab, and ipilimumab in treating kidney transplant recipients with selected unresectable or metastatic cancers. Principal Investigator: Evan J. Lipson. https://clinicaltrials.gov/ct2/show/NCT03816332. Accessed 2 Feb 2020

Dana Farber Cancer Institute (2020) Protocol: 19–817 (IRB pending). A phase I/II study of the safety and efficacy of cemiplimab (PD-1 blockade) in selected organ transplant recipients with advanced cutaneous squamous cell carcinoma (CONTRAC). Principal Investigator: Glenn J. Hanna

Kumar V et al (2020) The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist 25(6):505–514 CrossRef

Titel: Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy
verfasst von: Melissa J. Danesh
Patrick M. Mulvaney
Naoka Murakami
Leonardo V. Riella
Ann W. Silk
Glenn J. Hanna
Chrysalyne D. Schmults
Publikationsdatum: 25.06.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 9/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02644-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2020

In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy

Comparative immunomodulatory properties of mesenchymal stem cells derived from human breast tumor and normal breast adipose tissue

Aberrant peripheral blood CD4+ CD25+ FOXP3+ regulatory T cells/T helper-17 number is associated with the outcome of patients with lymphoma

Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone

Combining doxorubicin with stearylamine-bearing liposomes elicits Th1 cytokine responses and cures metastasis in a mouse model

Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie